iQure Pharma Secures US Patent for First-in-Class CNS Drug iQ-007 Targeting Glutamate Excitotoxicity
Key Insights
The USPTO has granted iQure Pharma (search) a patent for iQ-007, a first-in-class small molecule that enhances glutamate transporter (search) EAAT2 (search) activity to restore CNS glutamate balance.
iQ-007 is currently in Phase 1 clinical development for treatment-resistant epilepsy (search), with completion expected in December 2025.
The patent covers both composition of matter and medical use of the orally available compound, which targets excitotoxicity (search) across multiple CNS disorders (search).
iQure Pharma (search), a clinical-stage biotechnology company, announced on September 29, 2025, that the United States Patent and Trademark Office (USPTO) has granted a patent for its investigational drug iQ-007. The Princeton, New Jersey-based company describes iQ-007 as a first-in-class small molecule designed to restore glutamate balance in the central nervous system by addressing excitotoxicity (search)-related disorders.
Novel Mechanism Targets Glutamate Transporter
iQ-007 represents a breakthrough approach in CNS therapeutics by enhancing the activity of EAAT2 (search), the main glutamate transporter (search) in the brain. The orally available compound works by targeting astrocyte function, specifically the regulation of glutamate uptake that is essential for maintaining synaptic balance and protecting neurons from overstimulation.
"We're excited to secure US patent for iQ-007," said Pawel Zolnierczyk, CEO of iQure Pharma (search). "The US is one of the most important markets for new therapeutics. Importantly, the granted patent covers both composition of matter and medical use of iQ-007."
Clinical Development Progress
The compound is currently advancing through Phase 1 clinical development for treatment-resistant epilepsy (search), with expected completion in December 2025. This represents the first clinical validation of iQure's therapeutic approach to breaking the cycle of excitotoxicity (search)—a destructive feedback loop where excessive glutamate activity damages or kills nerve cells, driving neuronal damage and disease progression across multiple CNS conditions.
Broader Therapeutic Pipeline
Beyond epilepsy, iQure Pharma (search) is developing additional preclinical programs that leverage their glutamate homeostasis restoration platform. The company is targeting neurodegeneration (search) and pain conditions, expanding the potential applications of their core scientific approach.
Strategic Patent Protection
The newly granted patent provides comprehensive intellectual property protection, covering both the composition of matter and medical use of iQ-007. This milestone strengthens the commercial value of the therapy as the company continues advancing its clinical development program.
Zolnierczyk emphasized the significance of this achievement: "This milestone strengthens the value of this promising new therapy, and we look forward to advancing its clinical development."
The patent grant represents a significant validation of iQure's innovative approach to CNS disorders (search), positioning the company to advance what could become a new therapeutic paradigm for conditions characterized by glutamate dysregulation and excitotoxicity (search).